本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Allogene Therapeutics Inc.

1.96
-0.0450-2.25%
成交量:331.64萬
成交額:660.38萬
市值:6.74億
市盈率:-2.55
高:2.06
開:2.03
低:1.95
收:2.00
52周最高:4.46
52周最低:0.9842
股本:3.45億
流通股本:2.75億
量比:0.57
換手率:1.21%
股息:- -
股息率:- -
每股收益(TTM):-0.7663
每股收益(LYR):-0.8652
淨資產收益率:-52.32%
總資產收益率:-25.97%
市淨率:2.42
市盈率(LYR):-2.26

資料載入中...

2026/05/15

超過5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/05/15

超過5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/05/13

超過5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/05/13

超過5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/05/13

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2026/05/13

重要事件披露

Form 8-K - Current report
2026/04/23

超過5%披露

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
2026/04/21

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/04/15

重要事件披露

Form 8-K - Current report
2026/04/13

重要事件披露

Form 8-K - Current report
2026/04/13

重要事件披露

Form 8-K - Current report
2026/04/01

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/03/16

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/03/16

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/03/12

年度報告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2026/03/12

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2026/03/12

重要事件披露

Form 8-K - Current report
2026/03/02

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/02/02

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/02/02

關聯方擬減持公告

Form 144 - Report of proposed sale of securities